Champions Oncology, Inc.

NASDAQ:CSBR

Biotechnology

Healthcare
$4.44 -1.17%

-$0.08 today

Market cap
$61.80M
Beta
0.40
P/E (TTM)
-41.0
EPS (TTM)
-$0.16
52W Low $5.50High $9.63

Volume 0.01M

Average 0.01M

CSBR Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Champions Oncology, Inc.NASDAQ: CSBR

Gross Profit · Q3 FY2026 · quarter ended Jan 2026

Gross profit declines year over year

Q3 FY2026 gross profit of $7.73M fell 25.9% year over year, behind the -12.1% change in trailing-twelve-month gross profit. Sequentially, it fell 0.6% from the prior quarter. Over 3 fiscal years it compounded at +3.9% a year.

Context

  • Gross profit amounted to 50.1% of revenue in FY2025, up 8.8 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -25.9% toward the trailing-twelve-month pace of -12.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJan 2026
$7.73M-0.6% QoQ
Last fiscal yearApr 2025
$28.56M+37.6% YoY
LTMJan 2026
$26.58M-12.1% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.9%——
1 year+37.6%——
3-year CAGR+3.9%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
28.56M USD
Year-over-year change
+37.6%
4-year CAGR
+9.9%

Gross Profit vs competitors

How CSBR compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -12.1% is the 4th highest of 8, against a peer median of -86.1%.
  • Gross profit amounts to 45.9% of revenue for CSBR, versus a peer median of 98.7%.
CSBR Competitors
Gross Profit for CSBR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$98.33M USD+52.1%+17.0%98.7%
CSBRChampions Oncology, Inc.LTM Jan 2026$26.58M USD-12.1%+3.9%45.9%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$22.24M USD-86.1%—96.1%
CNTBConnect Biopharma Holdings LimitedFY2025$64K USD-99.8%—100.0%
KLRSKalaris Therapeutics IncLTM Mar 2026-$20K USD———
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026-$121K USD+2.4%-83.1%—
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026-$666K USD———
IMAImageneBio IncLTM Mar 2026-$780K USD+95.0%——
STTKShattuck Labs, Inc.LTM Mar 2026-$820K USD-146.7%—82.0%
IFRXInflaRx N.V.LTM Mar 2026-€7.23M EUR-142.9%—24646.3%
Peer median (excluding CSBR) —-86.1%-33.1%98.7%

Competitors are the stored peer set for CSBR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Apr 2021
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
Revenue41.04M49.11M53.87M50.16M56.94M
Cost of Revenue21.45M23.63M29.53M29.4M28.39M
Gross Profit19.59M25.48M24.34M20.75M28.56M
Gross Margin47.7%51.9%45.2%41.4%50.1%
Research & Development7.2M9.37M11.55M9.54M6.83M
Selling, General & Admin12.03M15.5M17.24M18.13M16.88M
Operating Expenses19.23M24.87M28.79M27.68M23.71M
Depreciation & Amortization1.18M1.63M2.25M1.87M1.64M
EBITDA1.55M2.21M(3.02M)(5.44M)6.27M
EBITDA Margin3.8%4.5%-5.6%-10.8%11.0%
Operating Income366K607K(4.45M)(6.92M)4.85M
Operating Margin0.9%1.2%-8.3%-13.8%8.5%
Interest Income00000
Interest Expense00000
Other Income / Expenses71K(24K)(818K)(387K)(220K)
Income Before Tax437K583K(5.27M)(7.31M)4.63M
Pre-Tax Margin1.1%1.2%-9.8%-14.6%8.1%
Income Tax Expense75K35K68K(32K)(75K)
Net Income362K548K(5.34M)(7.28M)4.7M
Net Margin0.9%1.1%-9.9%-14.5%8.3%
EPS (Basic)0.030.04(0.39)(0.54)0.34
EPS (Diluted)0.020.04(0.39)(0.54)0.33
Weighted Avg Shares13.14M13.2M13.54M13.55M13.66M
Weighted Avg Shares (Diluted)14.57M14.16M13.54M13.55M14.27M

Champions Oncology, Inc.

NASDAQ:CSBR

Intrinsic Alpha fair value

Locked

Current Price

$4.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.